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Abstract
Streptococcus pneumoniae (the pneumococcus) is a major cause of mortality and morbidity 
globally, and the leading cause of death in under-five year olds. The pneumococcal cytolysin 
pneumolysin (PLY) is a major virulence determinant, known to induce pore-dependent pro-
inflammatory responses. These inflammatory responses are driven by PLY-host cell membrane 
cholesterol interactions, with binding to a host cell receptor not previously demonstrated. 
However, here we discovered a receptor for PLY, whereby pro-inflammatory cytokine responses 
and TLR signaling are inhibited upon PLY binding to the Mannose-Receptor C type 1 (MRC-1) in 
human dendritic cells (DCs) and murine alveolar macrophages, along with upregulation of the 
cytokine suppressor SOCS1. Moreover, PLY-MRC-1 interaction mediates pneumococcal 
internalization into non-lysosomal compartments and polarizes naive T cells into an IFN-γlow, 
IL-4high and FoxP3+ immunoregulatory phenotype. In mice, PLY-expressing pneumococci co-
localize with MRC-1 in alveolar macrophages, and induce lower pro-inflammatory cytokine 
responses and reduced neutrophil infiltration, compared to a PLY-mutant. In vivo, MRC-1-
inhibition using blocking antibodies or MRC-1 deficient mice, show reduced bacterial loads in the 
airways. In conclusion, we show that pneumococci use PLY-MRC-1 interactions to downregulate 
inflammation and enhance bacterial survival in the airways. This has important implications for 
future vaccine design.
Streptococcus pneumoniae is a common colonizer of the upper respiratory tract of healthy 
children, but also a major cause of life-threatening diseases such as pneumonia, septicaemia 
and meningitis, resulting in death of over 800,000 children annually1. The cholesterol-
binding pore-forming toxin pneumolysin (PLY) is expressed by most disease-causing 
isolates and is required for virulence2,3 and host-to-host transmission4. PLY is a multi-
functional protein, which at sublytic doses can activate complement5, re-arrange 
cytoskeleton of host cells6, and induce pro-inflammatory cytokine responses7. PLY is 
released during bacterial autolysis, but has also been shown to be localized on the 
pneumococcal cell wall, thereby accessible to extracellular proteases8. The surface 
localization of PLY allows for speculation of a non-cholesterol receptor on host cells.
Alveolar macrophages and dendritic cells (DCs) are the major resident immune cells in 
alveoli and mediate protection from pathogens. The mannose receptor, MRC-1 (CD206), is a 
M2 phenotype marker9 and a phagocytic receptor10 that is mostly expressed by tissue 
macrophages, including alveolar macrophages11. MRC-1 binds to endogenous and 
microbial antigens such as capsular polysaccharides12,13. Furthermore, studies have 
demonstrated that MRC-1 influences pneumococcal uptake by Schwann and olfactory cells, 
but they did not show co-localization14,15. It is not clear which macrophage receptors 
recognize pneumococci in the nasopharynx and lungs and what bacterial properties interacts 
with the receptors mediating pneumococcal uptake. Here, we discovered a role for PLY in 
driving anti-inflammatory responses and lysosomal escape in macrophages and DCs by 
directly binding to MRC-1, thereby promoting pneumococcal internalization and survival in 
the host.
We first compared the cytokine response induced by PLY by infecting different immune 
cells, primary human monocyte-derived dendritic cells (DCs), neutrophils and THP-1 
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monocyte-derived macrophages, with a low dose (MOI of 1) of the pneumococcal strain 
T4R (expressing PLY), or its isogenic PLY mutant T4R∆ply. The non-encapsulated strain 
T4R (isogenic capsular mutant of the encapsulated serotype 4 strain T4) was used for the in 
vitro experiments to increase bacterial uptake since the capsule impedes bacterial adhesion 
to host cells16. We found lower secretion of the pro-inflammatory cytokines TNF-α, IL-1β 
and IL-12 from DCs challenged with PLY-proficient T4R compared to the mutant T4R∆ply, 
which was in contrast to THP-1-derived macrophages and neutrophils (Fig.1a, 
Supplementary Fig.1a-b). This PLY-dependent inhibition of cytokine responses was also 
observed using the encapsulated strains T4 and T4∆ply (Fig.1b). The cytokine inhibition 
was independent of cell death as determined by measuring LDH release (Supplementary Fig.
1c), but dependent on bacterial uptake since secretion of TNF-α was reduced by blocking 
phagocytosis using cytochalasin D and wortmannin (Supplementary Fig.1d). Treatment with 
cytochalasin D, an inhibitor of actin polymerization, inhibited cytokine production by DCs 
and THP-1 macrophages in a PLY-independent manner. Pre-treatment with purified 
endotoxin-free PLY at 100 ng/ml inhibited IL-12 production by ~50% from DCs infected 
with T4R∆ply in a dose-dependent manner, independent of cell death (Supplementary Fig.
1e). To study strain dependency and the influence of the challenge dose we then infected 
DCs, THP-1 macrophages, neutrophils and bone-marrow derived macrophages (BMDMs) 
with the pneumococcal strains D39 of serotype 2, or its isogenic PLY mutant, D39Δply, at 
different MOIs and measured IL-1ß release and cell death (Supplementary Fig.1f-i). We 
observed that at lower infection doses (MOI of 0.1 or 1), the mutant D39Δply induced 
higher levels of IL-1ß in DCs and BMDMs (but not in neutrophils and THP-1 macrophages), 
independent of cell death. However, at MOI of 10, the pattern was reversed and wild-type 
D39 induced higher IL-1ß release, but this was also accompanied by ~2 fold higher cell 
death.
We then performed a TLR signalling q-PCR array using RNA from DCs infected for 9hrs 
with T4R or T4R∆ply. Expression of all genes, except IFNβ1, was upregulated following 
infection with T4RΔply compared to T4R infected cells (Supplementary Fig.1j), indicating 
that PLY-expression has a general inhibitory effect on cytokine induction and inflammatory 
signalling in DCs.
To explore mechanisms behind this inhibitory effect of PLY on DCs, we measured 
expression of the negative regulators of NF-κB, AP-1 and STAT1 pro-inflammatory 
signalling pathways. We identified upregulation of Suppressor of Cytokine Signalling 1, 
SOCS117, mRNA in DCs infected with T4R, but not with T4R∆ply (Fig.1c). Kinetic 
analysis revealed that SOCS1 mRNA increased 6hrs post infection (pi) and peaked at 9hrs 
(Supplementary Fig.1k). Concurrent with mRNA, protein levels of SOCS1 were higher in 
DCs at 9hrs pi with T4R compared to T4R∆ply (Fig.1d). However, SOCS1 expression 
remained unaffected in THP-1 macrophages, (Supplementary Fig.1l), confirming the cell-
type specific effect.
Since SOCS1 is a known inhibitor of STAT signalling18, we measured phosphorylated 
STAT1 and found delayed phosphorylation in T4R-infected DCs as compared to T4RΔply 
(Fig.1e). Pre-treatment with the STAT inhibitor stattic inhibited secretion of TNF-α, IL-1ß 
and IL-12 (Supplementary Fig.1m-o). Besides STAT1, we also found lower levels of NF-κB 
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in T4R-infected DCs compared to T4RΔply (Fig.1f). Together, our data suggest that PLY-
expression inhibits pro-inflammatory signalling via STAT1 and NF-κB in DCs, possibly via 
induction of the cytokine suppressor, SOCS1.
To identify the host receptor interacting with PLY, we performed a pull-down assay using 
purified PLY. We identified 32 proteins exclusively from DC lysates of which three were 
surface proteins, Integrin alpha-M, Mannose Receptor C type 1 (MRC-1), and Galectin-1 
(Supplementary Table 1). We further investigated the lectin receptor MRC-1, since it has 
previously been reported to have immunosuppressive properties19. To confirm the 
interaction between MRC-1 and PLY, we performed immunoprecipitation of MRC-1 from 
native DC lysates using anti-PLY coupled beads (Supplementary Fig.2a). To assess whether 
MRC-1 binding to PLY was mediated via glycan recognition, we performed enzymatic 
deglycosylation of PLY to remove bound glycans as evident by slightly higher 
electrophoretic gel mobility (Supplementary Fig.2b). Importantly, MRC-1 co-
immunoprecipitated with both native and deglycosylated PLY from native DC lysates 
(Supplementary Fig.2c). We found that MRC-1 was selectively expressed by DCs and M-
CSF derived macrophages (M2 polarized), but not by THP-1, neutrophils or GM-CSF 
derived macrophages (M1 polarized) (Supplementary Fig.2d-e). Interestingly, DCs 
upregulated MRC-1 expression upon infection with T4R, compared to T4RΔply 
(Supplementary Fig.2f). Similar to human DCs, BMDMs isolated from wild-type, but not 
MRC-1-/- mice, upregulated the MRC-1 protein upon infection with strain D39 as compared 
to its isogenic PLY-deficient mutant, D39Δply (Supplementary Fig.2g). The capsular mutant 
(D39∆cps) induced lower upregulation of MRC-1 than D39 (Supplementary Fig.2h). 
Analysis of MRC-1 expression at different MOIs revealed that DCs and BMDMs 
upregulated MRC-1 in a dose-dependent way in response to D39, as compared to D39∆ply, 
and the difference was significant at MOI of 1 (Supplementary Fig.2i-l). Neutrophils and 
THP-1 macrophages showed very low MRC-1 expression that did not change significantly 
upon infection. Surface plasmon resonance analysis confirmed the PLY-MRC-1 interaction 
showing a KD value of 4.5x10-8 M (Fig.2a). The interaction was also verified in the reverse 
orientation (Supplementary Fig.2m), and the specificity was shown using control proteins 
(Supplementary Fig.2n). To study the specific interaction of MRC-1 with PLY versus 
capsular polysaccharides, we performed ELISA to measure binding of immobilized MRC-1 
with PLY dose-dependently in the presence or absence of purified serotype 2 or 4 capsules. 
We found that MRC-1 binds to the type 2, but not the type 4 capsule (Supplementary Fig.
2o). Importantly, MRC1 still binds to PLY even in the presence of capsule although to lesser 
extent (Supplementary Fig.2o). To identify the region of interaction, we performed a solid-
phase binding assay using purified PLY domains and an Fc-construct containing the 
mannose-binding C-type lectin-like carbohydrate recognition domains of MRC-1 
(CTLD4-7-Fc). We found that domain 4 of PLY is key to MRC-1-PLY-interaction as 
purified domain 4, but not domains 1-3, bound the CTLD4-7-Fc construct (Fig. 2b). The 
non-pore-forming PLY mutant (PdB)20 showed reduced binding compared to cytolytic PLY 
(Fig.2b), indicating that active PLY is required for MRC-1 binding.
Next, we investigated the localization patterns of MRC-1 and PLY in DCs using 
immunofluorescence microscopy. Wild-type DCs or MRC-1-deficient DCs (treated with 
MRC-1 siRNA), were incubated for 45 min with recombinant active PLY. PLY co-localized 
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with MRC-1 and the early endosomal antigen EEA-1, indicating uptake by DCs (Fig.2c). In 
contrast, PLY-binding was reduced in MRC-1-deficient DCs. In addition, the non-
poreforming PLY mutant (PdB) did not co-localize with MRC-1 (Fig.2c). At 90 min post 
pneumococcal challenge, internalized T4R co-localized with MRC-1, but did not co-localize 
with lysosomes, while the converse was observed for T4RΔply (Fig.2d). To test whether 
bacterial internalization via MRC-1 inhibits fusion of pneumococcal-infected vacuoles with 
lysosomes, we used antibody-opsonized pneumococci as a control to engage Fc gamma 
receptor-mediated phagocytosis21. Strikingly, opsonized T4 did not co-localize with MRC-1 
and co-stained with lysosomes in contrast to the non-opsonized control (Supplementary Fig.
2p). Moreover, opsonized T4 elicited similar levels of TNF-α and IL-1β from DCs as 
T4∆ply (Supplementary Fig.2q). To explore whether active PLY is required for interaction 
with MRC-1 in clinical pneumococcal isolates, we used a serotype 1 strain expressing non-
haemolytic PLY (BHN31 of ST306) and the clonally related haemolytic strain (BHN32 of 
ST228)22. We found that the non-haemolytic strain did not co-localize with MRC-1, but co-
stained for lysosomes (Supplementary Fig.2r), and elicited higher cytokine production from 
DCs (Supplementary Fig.2s) as compared to the haemolytic strain. Together, our data 
suggest that pneumococcal internalization, due to interaction between active PLY and 
MRC-1, inhibits fusion of vacuoles containing pneumococci with lysosomes. This is 
supported by previous findings that MRC-1 regulates phagosomal trafficking following 
phagocytosis and limits fusion with lysosomes10,23.
Furthermore, we found that uptake of PLY-proficient T4R, but not T4R∆ply, was reduced by 
50% in MRC-1 depleted DCs (Fig.3a and Supplementary Fig.3a). Also, depletion of MRC-1 
in DCs led to significantly higher levels of IL-12, TNF-α and IL-6 upon T4R-infection (Fig.
3b), and abrogated SOCS1 expression (Supplementary Fig.3b). This suggests that activation 
of MRC-1 by PLY triggers upregulation of SOCS1 in DCs, thereby reducing secretion of 
inflammatory cytokines.
Since DCs are professional antigen-presenting cells, we investigated the role of MRC-1 in 
DC-primed CD4+ T-helper cell cytokine responses after pneumococcal challenge. We found 
that DCs depleted of MRC-1 using siRNA and infected with T4R (in contrast to T4RΔply), 
elicited higher IFN-γ (Th1 cytokine) and lower IL-4 (Th2 cytokine) levels from naive T-
helper cells in co-culture, compared to DCs treated with control siRNA (Fig.3c-d). A similar 
trend was observed in DCs stimulated with purified PLY. To further characterize the 
phenotype of T cells co-cultured with DCs, we measured FoxP3, a regulatory T cell 
marker24 and found that DCs infected with T4R (but not with T4RΔply) and those treated 
with purified PLY, induced higher FoxP3 expression in naive T helper cells upon co-culture 
(Fig.3e, Supplementary Fig.3c). FoxP3 upregulation in T cells was abolished when co-
cultured with DCs treated with MRC-1 siRNA. Similar to human DCs, murine BMDMs 
from WT mice that were infected with D39 (in contrast to D39Δply) and co-cultured with 
CD4+ murine T cells, resulted in higher regulatory (FoxP3, IL-10 expressing) T cells and 
lower Th1 cells (T-bet, IFN-γ expressing) as compared to BMDMs from MRC-1-/- mice 
(Fig.3f, Supplementary Figs. 3d-f). Our data are in agreement with earlier findings showing 
that MRC-1 expression in DCs inhibits CD45 and induces T-cell tolerance25, and that PLY 
is required for robust regulatory T cell induction in vivo26.
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To verify our findings in vivo, we challenged wild-type C57BL/6J mice intranasally with 
106 CFU of wild-type T4 or the mutant T4Δply. At 6hrs post infection (pi), bronchoalveolar 
lavage fluids (BALF) were collected and lung alveolar macrophages isolated. We observed 
intracellular co-localization of strain T4 with MRC-1, but not with lysosomes (Fig.4a). In 
contrast, intracellular T4Δply did not co-localize with MRC-1, but co-stained with 
lysosomes (Fig.4a, Supplementary Fig.4a). Ex vivo, murine alveolar macrophages secreted 
lower levels of pro-inflammatory cytokines upon infection with T4R compared to T4RΔply. 
This difference was reduced by pre-treatment with anti-MRC-1 (Supplementary Fig.4b-c). 
In agreement with these results, T4Δply infected mice had higher levels of pro-inflammatory 
cytokines, TNF-α, IL-12 and IL-1β, and lower levels of anti-inflammatory cytokines, IL-10 
and TGF-β, in the BALF, compared to mice infected with T4 (Fig.4b, Supplementary Fig. 
4d). In addition, T4∆ply infected mice had higher numbers of neutrophils and monocytes in 
the BALF (Supplementary Fig.4e). The enhanced inflammation and higher infiltration of 
phagocytes were concurrent with the higher clearance of T4∆ply compared to T4 from the 
airways of infected mice (Fig.4c). Mice pre-treated with antibodies to block MRC-1 prior to 
infection with T4 had significantly higher levels of TNF-α and IL-12, and lower levels of 
IL-10 in BALF at 6hrs pi as compared to isotype antibody-treated controls (Fig.4d, 
Supplementary Fig.4f). Anti-MRC-1 treated mice had 50% lower bacterial counts in the 
lower airways compared to controls (Fig.4e), and intracellular bacteria did not co-localize 
with MRC-1 in alveolar macrophages (Supplementary Fig.4g). Importantly, MRC-1-/- mice 
also had significantly decreased bacterial numbers in the nasopharynx at 7 and 14 days post 
challenge compared to wild-type mice in a pneumococcal carriage model with strain D39 
(Fig.4f). In wild-type mice, MRC-1+ macrophages were found to rapidly accumulate in the 
nasopharynx following pneumococcal colonization (Supplementary Fig.5a-b). Similar to 
anti-MRC-1 treated mice, MRC-1-/- mice had higher levels of pro-inflammatory cytokines, 
TNF-α and IL-6, and lower levels of anti-inflammatory IL-10 and TGF-β in the 
nasopharynx compared to WT mice at 6hrs and 1 day pi (Supplementary Fig.5c-f).
MRC-1 mediated phagocytosis is of particular significance in the lungs, as MRC-1 is 
abundantly expressed by alveolar macrophages. A previous study by Dorrington et al. 
highlighted the crucial role of the scavenger receptor MARCO in anti-pneumococcal 
immunity in the nasopharynx and suggested a minimal role for MRC-127. However, the 
authors in that study used a 100-fold higher infection dose (1x107 CFU) for colonization 
compared to our study and we have previously shown that in contrast to high-density 
infection, low density pneumococcal carriage induces immunoregulatory responses 
characterized by sustained elevation of nasopharyngeal TGF-β1, regulatory T cells and 
MRC-1 expressing macrophages26. In the current study, we demonstrate that the infection 
dose determines the nature of cytokine response to PLY, where lower infection doses 
eliciting cytokine inhibition. Hence, our results suggest that the infection dose is critical 
when studying host responses to pneumococcal infections.
PLY is not a typical adhesin and has previously been considered to be cytosolic and released 
only upon bacterial lysis. However, recent data using transmission electron microscopy28 
show that pneumolysin can be surface localized, suggesting that is can be available for 
interactions with host receptors. The above data support our discovery that PLY interacts 
with MRC-1 which is a finding that represents a conceptual change in our current 
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understanding. Our results suggest that MRC-1-PLY interaction is not mediated by glycan 
recognition, since MRC-1 also binds to deglycosylated PLY, and the interaction is 
specifically mediated by C type lectin domains 4-7 of MRC-1 and domain 4 of PLY.
In conclusion, we discovered a significant role for PLY, whereby MRC-1 acts as a receptor 
for PLY, enabling pneumococci to invade MRC-1-proficient immune cells including DCs 
and alveolar macrophages in the airways, thereby dampening cytokine responses to establish 
intracellular residency of pneumococci. Whilst MRC-1 has previously been demonstrated to 
bind pneumococcal capsular polysaccharides12,13, we show here that it can also directly 
bind to PLY. This is a hitherto unknown survival mechanism for the pneumococcus and has 
important implications for future vaccine design against infection. The potential mechanisms 
involved are summarized in Fig.4g.
Methods
Pneumococcal strains used
The encapsulated S. pneumoniae serotype 4 strain TIGR4 (T4; ATCC BAA-334) as well as 
its non-encapsulated isogenic mutant, T4R, and their isogenic PLY-deficient mutants T4∆ply 
and T4R∆ply were used in this study. Clinical isolates of serotype 1 pneumococci expressing 
non-hemolytic PLY (BHN31 of ST306) or clonally related strain expressing haemolytic 
PLY, (BHN32 of ST228) were also used22. Bacteria were grown on blood agar plates at 
37°C and 5% CO2 overnight. Colonies were inoculated into C+Y medium and grown until 
exponential phase (OD620 = 0.5). For opsonisation, pneumococci were incubated with 5% 
Type 4 anti-serum for 30 min at 37°C (Statens Serum Institut).
S. pneumoniae serotype 2, strain D39 (NCTC 7466), was obtained from the National 
Collection of Type Culture, London, UK. The pneumolysin-deletion D39 mutant D39∆ply 
was kindly provided by Prof. Tim Mitchell (University of Birmingham). Capsular-deficient 
D39-J (D39∆cps) and the double mutant in PLY and the capsule DKO (double knockout) 
(D39∆cps∆ply) were kindly provided by Dr. Lucy Hathaway (University of Bern). D39 was 
cultured on blood agar base with 5% v/v horse blood, or in brain heart infusion broth (BHI; 
Oxoid, Basingstoke, UK) with 20% v/v FBS (Sigma), supplemented with 20 mg/ml 
spectinomycin (Sigma) for DKO.
Pneumolysin (PLY)
Recombinant PLY, mutant (PdB) or PLY domains (D1-3, D4), were expressed in E. coli and 
purified as previously described7. PLY D1-3 and D4 were kindly provided by Prof. Tim 
Mitchell (University of Birmingham). Haemolytic activity of PLY was 100,000 HU/mg. 
Purified toxin was passed six times through an endotoxin removal column (Profos AG, 
Germany) and absence of detectable LPS was confirmed with PyroGene Recombinant 
Factor C assay (Lonza; detection limit 0.01 EU/ml).
Cell isolation from buffy coats, cell-culture and infection
Monocytes were purified from buffy coats of healthy donors (Karolinska University Hospital 
and Uppsala University Hospital) using the RosetteSep™ monocyte purification kit (Stem 
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Cell Technologies) and Ficoll-Paque Plus (GE Healthcare) gradient centrifugation. For 
differentiation into DCs, monocytes were cultured in R10 (RPMI 1640, 2 mM L-glutamine, 
10% FBS) Supplementaryemented with GM-CSF (40 ng/ml) and IL-4 (40 ng/ml) from 
Peprotech for 6 days. DCs were verified by flow cytometry to be >90% CD1a+ CD11c+. In 
co-culture experiments, at 24 hrs post infection, DCs were washed and incubated with naïve 
CD4+ T cells in a 1:10 ratio (DC: T cells) at 37°C. Supernatants were collected 5 days later 
for cytokine measurements by ELISA. Cytokine values were subtracted from control wells 
containing DCs alone. For infection, DCs were incubated with pneumococci at a multiplicity 
of infection (MOI) of 1 and extracellular bacteria were killed with 200 µg/ml gentamicin 
after 2 hrs of infection. Cytochalasin D (0.5 mM), wortmannin (0.1 mM) (Sigma) or stattic 
(5 μM) (Tocris Biosciences) were added to cells 15 min prior to pneumococcal infection. In 
some experiments, DCs were incubated with endotoxin-free PLY at 0.2 μg/ml diluted in R10 
medium.
Human monocytic leukemia THP-1 cells (ATCC TIB-202) were cultivated in R10. For 
differentiation into macrophages, THP-1 cells were treated for 48 hrs with 20 ng/ml of 
phorbol myristate acetate (PMA) (Sigma).
Neutrophils were isolated from whole blood upon lysis of RBCs and enriched using the 
EasySep human neutrophil enrichment kit (StemCell Technologies) according to the 
manufacturer’s instructions. Purified neutrophils were verified to be ~99% CD66b+CD16+. 
Human naive T cells were purified from fresh PBMCs using the EasySep™ Human Naive 
CD4+ T Cell Isolation Kit (Stem cell Technologies) and were verified by flow cytometry to 
be >95% CD3+CD4+. All cells used in this study were mycoplasma tested.
Isolation of mouse bone-marrow derived macrophage (BMDM) and culture
Bone-marrow cells were flushed from murine femurs and tibia. Macrophages were grown 
from bone marrow cells in Dulbecco’s Modified Eagle’s Medium (Sigma, UK) 10% v/v 
foetal calf serum (FCS; Sigma), 100 U/ml penicillin, 100 mg/ml streptomycin, and 100 mM 
L-glutamine (Sigma) Supplementaryemented with 20 ng/ml macrophage colony-stimulating 
factor (M-CSF; R&D systems). Cultures were maintained in a humidified atmosphere (5% 
CO2) at 37°C, and medium was replaced on days 3 and 6. On day 6, cells were plated for 
use in assays. 6.25x105 BMDM were cultured alone (untreated) or infected with D39, 
D39∆ply, D39∆cps or DKO (D39∆cps∆ply)(1 macrophage: 10 bacteria) or stimulated with 
purified PLY (4 μg/ml). After 24 hrs incubation, supernatants were collected and used to 
assess cytokine production by ELISA or determine density of infection by Miles and Misra 
dilution.
BMDM-T cell co-culture
Naive CD25-CD4+ T cells were purified from spleen of C57BL/6 or MRC-1-/- mice by 
negative selection (Miltenyi Biotec). Non-CD4+ T cells and CD44+ memory T cells were 
labelled with biotinylated antibodies, before addition of anti-biotin microbeads and magnetic 
separation. CD4+ T-cell purity was >90%. Purified T-cells were added to 24 hrs 
pneumococcal stimulated BMDM at a ratio of 15:1 for 5 days. Culture supernatants were 
collected for ELISA and cells were stained for flow cytometry.
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Cell viability assays
Cytotoxicity was determined in the culture supernatants by measuring the release of the 
enzyme lactate dehydrogenase (LDH) compared to a 100% lysis control using the 
Cytotoxicity kit (Roche) according to manufacturer’s instructions.
Real time quantitative PCR (qPCR)
Total cellular RNA was extracted from cells using the RNeasy Kit (Qiagen). The 
concentration and purity of isolated RNA was determined spectrophotometrically with the 
Nanodrop ND 1000. cDNA was synthesized from the isolated RNA using the High Capacity 
cDNA Reverse Transcription kit (Applied Biosystems). The qPCR was performed using the 
iTaq Universal SYBR Green Supermix (BioRad) according to manufacturer’s instructions. 
The following primers were used: Hs_SOCS1_1_SG, Hs_MRC1_1_SG and 
Hs_GAPDH_1_SG. Each primer pair was validated for specificity by performing melt curve 
analysis of the PCR product to ensure the absence of primer dimers and unspecific products. 
The mRNA expression level was normalized to the level of GAPDH and relative expression 
was determined with the ∆∆CT method. The TLR Signaling qPCR array (Qiagen) was 
performed according to the manufacturer’s instructions and analysed with the GeneGlobe 
Data analysis Center (Qiagen).
Mouse experiments and isolation of alveolar macrophages
All mice experiments were performed in accordance with the local ethical committee 
(Stockholms Norra djurförsöksetiska nämnd). Six- to seven- weeks old male wild-type 
C57BL/6J were used. Experiments with MRC-1-/- mice were done at the University of 
Liverpool with the approval of the UK Home Office and the University of Liverpool ethics 
committee. MRC-1-/- mice29 were generated on a mixed 129SvJ and C57BL/6 background, 
and then backcrossed to C57BL/6 strain for at least 7 generations. Homozygous knockout 
mice were bred and maintained at the University of Nottingham and were a generous gift of 
Dr. Luisa Martinez-Pomares (University of Nottingham). WT and MRC-1-/- mice used for 
infection were sex and age matched and no more than 12 weeks of age at the start of the 
experiment. WT and MRC-1-/- mice were randomised independently to time points by 
technical staff with no role in study design. Researchers were blinded to the experimental 
group until the data analysis stage. Sample size calculations were determined to give 90% 
power, alpha = 5%, assuming expected mean CFU for WT of 1000 CFU/ml and S.D. of 5% 
(determined from previous studies). The experiments were powered to detect an expected 
difference between groups of 10%.
Pneumococcal nasopharyngeal carriage model
For induction of pneumococcal nasopharyngeal carriage, mice were lightly anaesthetized 
and 10 μl PBS containing 1x105 CFU D39 was administered into the nostrils. The dose was 
confirmed by viable count following infection. At pre-chosen time intervals following 
infection, mice were sacrificed and nasopharynx, draining cervical lymph nodes and lungs 
were collected, passed through a 30 μm cell strainer or homogenized with an Ultra-Turrax 
T8 homogeniser (IKA, Germany). Bacterial counts were determined from tissue 
homogenates by viable count on blood agar plates.
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Invasive pneumococcal disease model
Mice were sedated by inhalation of 4% isofluorane and 50 µl PBS containing 106 CFU of 
wild-type T4 or the PLY mutant, T4∆ply was administered into the nostrils. To block 
MRC-1, 20 µl of 0.1 mg/mL monoclonal anti-MRC-1 (Abcam) or isotype matched control 
(Abcam) was administered intranasally 30 min before infection. Post sacrifice, the lungs 
were perfused twice with ice-cold PBS containing 1 mM EDTA to collect the 
bronchoalveolar lavage fluid (BALF). To determine viable bacterial counts, serial dilutions 
of BALF were plated on blood agar plates followed by colony counting. Aliquots of BALF 
were frozen at -80°C for cytokine quantification by ELISA. To isolate alveolar 
macrophages, BALF was spun down at 400 g for 7 min at 4°C, resuspended in R10 medium 
(RPMI 1640 containing 2 mM L-glutamine and 10% foetal bovine serum (FBS)) and plated 
on coverslips for 1 hr to allow cells to attach. Unattached cells were removed by washes 
with PBS. Macrophages were verified phenotypically by flow cytometry (CD11c+ Siglec F
+). The percentage of neutrophils (CD11bhi Ly6Ghi) and monocytes (CD11bhi Ly6Chi) in the 
BALF was quantified by flow cytometry upon gating for viable cells stained using fixable 
viable dye eFluor 780 (Thermo Fisher Scientific).
MRC-1 knockdown using siRNA
DCs (6 x 106) were electroporated with 5 µM siRNA from Life Technologies against 
MRC-1 (s53926, s53927, s53928) or scrambled control siRNA (4390843, 4390846) on day 
4 of DC differentiation. The cells were electroporated with the Bio-Rad gene pulser (square 
wave, 500V, 0.5 ms with a single impulse) and immediately resuspended in fresh R10 
medium. The cells were used 48 hrs post siRNA electroporation. Treatment with siRNA 
reduced MRC-1 protein expression by ~80% as evaluated by western blotting (Fig. S3A).
Flow Cytometry
Cells were fixed with 4 % PFA and stained with a mouse anti-MRC-1 (Abcam) and a goat-
anti mouse Alexa Fluor 488 secondary antibody (Life Technologies). For intracellular 
staining, cells were fixed with 4% PFA and permeabilized with ice cold methanol. Cells 
were stained with phospho-STAT1 (Tyr 701) Alexa Fluor 488 conjugated rabbit antibody 
(Cell Signalling), rabbit anti-SOCS1 (ab135718) and assessed by flow cytometry using the 
Gallios Flow Cytometer. In addition, the following antibodies from Biolegend were used in 
this study : CD3 (100235), CD4 (100405), CD8a (100707), CD11b (101207), CD19 
(152403), CD45 (103111), CD69 (104507), CD115 (135523), CD206 (MRC-1) (141707), 
F4/80 (123107), FOXP3 (126403), GATA3 (653805), Gr-1 (108411), MARCO (BioRad 
ED31), RORγt (654301), T-bet (644809). Antibodies were conjugated to fluorescein 
isothiocyanate (FITC), phycoerythrin (PE), PE-Cy7 or allophycocyanin (APC) and 
appropriate isotype controls were included in all experiments.
Quantification of cytokines
For cytokine measurement, cell-free culture supernatants were harvested 18 hrs pi and 
frozen at -20°C. The levels of human TNF-α, IL-12p70, IL-1ß, IFN-γ and IL-4, using the 
OptEIA™ ELISA kit (BD Biosciences). The levels of mouse TNF-α, IL-12p70, IL-1ß, 
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IL-10 and TGF-ß in the mouse BALF was measured using the respective mouse ELISA kits 
(BD Biosciences).
Enzymatic deglycosylation of PLY
PLY was deglycosylated under native conditions using the Protein Deglycosylation kit 
(Sigma) following the instructions of the kit. Briefly, 10 μg of recombinant PLY was 
incubated with 1 μl each of Peptide:N-glycosidase F, O-Glycosidase, Sialidase A, ß-(1-4)-
Galactosidase and ß-N-acetylglucosaminidase in 50 μl reaction buffer for 3 days at 37°C. 
The extent of deglycosylation was assessed by mobility shifts on SDS-PAGE gels.
Pull-down of PLY-interacting proteins and Co-IP with MRC-1
To identify proteins interacting with PLY, pull-down was performed on DC and THP-1 
native cell lysates using recombinant PLY as the bait. Cells were lysed with native lysis 
buffer (Abcam) containing 1x protease inhibitors (Roche) on ice for 15 min. Briefly, lysate 
corresponding to 0.8 mg protein was precleared by incubating with Protein G-agarose beads 
(Pierce) for 30 min at 4°C. Subsequently, the precleared lysate was incubated with 1 μg PLY 
(Cusabio) for 1 hr at 4°C and then incubated with Protein G beads conjugated to mouse anti-
PLY (Abcam) with gentle rotation overnight at 4°C. As a control, lysates were incubated 
with isotype antibody or beads alone to distinguish non-specific interactions. The beads 
were washed thrice with PBS and the bound proteins were eluted by boiling in NuPAGE 
LDS sample buffer for 5 min at 95°C. The eluted proteins were identified using mass 
spectrometry at the Science for Life Laboratory in Uppsala, Sweden. The protein 
identifications were based on at least two matching peptides of 95% confidence per protein. 
To confirm the interaction between PLY and MRC-1, western blotting was performed on the 
eluate. MRC-1 was detected using rabbit anti-human MRC-1 (Abcam) and HRP-conjugated 
secondary goat anti-rabbit (GE Healthcare).
Surface plasmon resonance analysis
Surface plasmon resonance experiments were run on Biacore 3000 and T200 instruments 
(GE Healthcare) at 25°C with 10 mM HEPES Supplementaryemented with 2 mM CaCl2 and 
0.1 % (v/v) Tween 20 as running buffer. Pneumolysin (PLY; Causabio) and mannose 
receptor C type 1 (MRC-1; R&D Systems) were diluted to 10 μg/mL in 10 mM NaOAc pH 
4.5 and immobilized on CM5 chips by amine coupling to immobilization levels of 2200 and 
12000 RU, respectively. PLY was buffer-exchanged into running buffer using a 3 kDa 
MWCO Amicon centrifugal filter device prior to injections. Human serum albumin was 
immobilized at 11000 RU in a separate flow cell as a negative control. Analytes were 
injected at 30 μl/min and surfaces were regenerated using 10 mM HCl. Sensorgrams were 
double referenced using a blank flow cell and a buffer injection. Data for injections of PLY 
over MRC-1 were fitted to a Langmuir 1:1 interaction using BiaEval 4.1 software and the 
dissociation equilibrium constant was calculated from average association and dissociation 
rate constants obtained from three separate dilution series analyzed on two different sensor 
chips. Human serum albumin, bovine serum albumin and Trastuzumab (Herceptin®) were 
injected at 1 μM as negative controls for non-specific binding. The influence of mannose on 
MRC-1 binding was evaluated by pre-incubating 100 nM of MRC with 0.5 mM D-mannose 
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or D-glucose (Sigma) for 1 hr in running buffer prior to injection of the mixed samples over 
the PLY immobilized chip.
ELISA to measure MRC-1-PLY binding
Briefly, 96-well flat-bottomed plates (Sigma, UK) were coated overnight with 1.25-10 μg/ml 
of mannose receptor, full-length (2534-MR-050) or truncated constructs CTLD4-7-Fc, CR-
FNII-CTLD1-3-Fc30, a generous gift from Dr Luisa Martinez-Pomares (University of 
Nottingham, UK), in the presence or absence of galactose or mannose (Sigma, UK) in 
coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6). Wells were blocked with 200 μl 
of 20% (v/v) FBS in PBS for 2 hrs, and then washed three times with 250 μl PBS, 0.05% 
(v/v) Tween 20 (Sigma, UK). 10 μg/ml of PLY, PdB, PLY domains 1-3 or PLY domain 4 
was added and incubated at 37ºC for 1 hr. Wells were washed again with PBS and bound 
proteins were detected using PLY polyclonal antibody (Abcam ab71811) in blocking buffer. 
Plates were incubated with anti-rabbit IgG alkaline phosphatase (Abcam ab6722) in 
blocking buffer. Bound antibodies were detected in using the chromogenic substrate p-
nitrophenylphosphate (pNPP) for 30 min. 1M NaOH was added to all wells and the 
absorbance was measured at 405 nm.
To study the specific interaction of MRC-1 with PLY versus capsular polysaccharides, 
immobilized MRC1 was incubated with PLY (0-5 μg/ml) in the presence or absence of 2.5 
μg/ml of purified serotype 2 or type 4 capsules (SSI Diagnostica). Bound PLY in the 
presence or absence of capsule was detected using mouse anti-PLY and anti-mouse IgG-
HRP. Binding of purified capsule to MRC-1 was detected using rabbit anti-capsule and anti-
rabbit IgG-HRP. Bound antibodies were detected using the chromogenic substrate, 
tetramethylbenzidine (TMB). 1M phosphoric acid was used as stop solution and absorbance 
was measured at 450 nm.
Immunofluorescence microscopy
Briefly, cells were fixed with 4% paraformaldehyde buffered in PBS for 10 min. 
Subsequently, the cells were permeabilized using PBS containing 0.5% Tween20 for 15 min. 
To block non-specific interactions, cells were incubated with 5% FBS in PBS for 1 hr. 
Lysosomes were stained using lysotracker deep red (Thermo Fisher Scientific) prior to 
fixation. Early endosomes were stained using Alexa 647conjugated anti-EEA1 (Abcam). 
PLY was stained using mouse anti-PLY (Abcam) and Alexa488-goat anti-mouse secondary 
antibody (Thermo Fisher Scientific). MRC-1 was detected using rabbit anti-MRC-1 
(Abcam) and Alexa 555-goat anti-rabbit secondary antibody (Thermo Fisher Scientific). 
Pneumococci were stained using rabbit anti-pneumococcal anti-serum (Eurogentec) labeled 
with Alexa 488 using Zenon rabbit IgG labeling kit (Thermo Fisher Scientific). Type 1 
clinical strains were stained using anti-serum Type 1 (Statens Serum Institut). Samples were 
washed twice with PBS between the antibody incubations and mounted on slides using 
ProLong Diamond antifade reagent containing DAPI (Thermo Fisher Scientific). Images 
were acquired using the Delta Vision Elite microscope under the 100x objective (GE 
Healthcare).
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Immunohistochemistry
Draining cervical lymph nodes were snap frozen in liquid nitrogen and 7 μm sections were 
cut. Staining was performed with fluorochrome conjugated MRC-1 (biotin 647, BD 
biosciences) and appropriate isotype matched controls. Sections were mounted in ProLong 
Gold (Invitrogen) and images were taken using a Zeiss Axioplan LSM 510 confocal 
microscope as single optical slices of between 0.8 and 1.0 μm. Images were analyzed using 
Zeiss LSM image browsing software v4.
Western blotting
Cells were lysed with RIPA buffer containing 1× protease inhibitors (Roche) on ice for 15 
minutes. Cell debris and nuclear material were pelleted by centrifuging at 13000 rpm for 15 
min. Lysate corresponding to 25 µg protein was boiled for 5 min at 95°C in NuPAGE LDS 
sample buffer and resolved on 4-12% Bis-Tris gel (Invitrogen). Proteins were transferred to 
polyvinylidene fluoride (PDVF) membrane and blocked with 5% skim milk powder in PBS 
containing 0.1% Tween-20. Proteins were detected using the following antibodies: mouse 
anti-human MRC-1 (Abcam), SOCS1 antibody, NFκB(p65) antibody (Santa Cruz) and a 
phospho-IκBa (Ser32) (Santa Cruz). Rabbit anti-GAPDH (Sigma) and Rabbit Histone 
H2A2.Z (Cell signaling Technologies) was used as a loading control. Anti-rabbit IgG or 
anti-mouse IgG conjugated to horseradish peroxidase (GE Healthcare) were used as 
secondary antibodies. Blots were developed with Amersham™ ECL Plus Western blotting 
detection system (GE Healthcare), using a ChemiDoc™ XRS+ (Bio-Rad Laboratories).
Statistical analysis
Data were statistically analysed using GraphPad Prism 5.04. Data of immune cells prepared 
from human donor blood were analysed with a Wilcoxon matched-pairs signed rank test. 
Data from THP-1 macrophages were analysed with a Mann Whitney test. Comparison 
between groups was done with a one-way or two-way ANOVA followed by a Bonferroni or 
Tukey’s post-test as indicated. Normalized data was analysed with an unpaired t-test. 
Differences were considered significant at *P < 0.05, **P < 0.01 and ns denotes not 
significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
The work in Sweden was supported by grants from the Swedish Research Council, Stockholm County Council, the 
Swedish Foundation for Strategic Research (SSF), and the Knut and Alice Wallenberg foundation. The work in 
Liverpool was supported by funding from the UK Medical Research Council (Programme Grant MR/P011284/1), a 
Sir Henry Dale Fellowship (awarded to D.R.N.) and jointly funded by the Welcome Trust and the Royal Society 
(Grant Number 204457/Z/16/Z), a British Commonwealth Scholarship (awarded to S.K.), Embassy of the Kingdom 
of Saudi Arabia Scholarship (awarded to H.M.) and the Institute of Infection & Global Health, University of 
Liverpool. We thank the Science for Life Laboratory Mass Spectrometry Based Proteomics Facility in Uppsala for 
the LC-MS analysis.
Subramanian et al. Page 13
Nat Microbiol. Author manuscript; available in PMC 2019 May 12.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
References
1. Black RE, et al. Global, regional, and national causes of child mortality in 2008: a systematic 
analysis. Lancet. 2010; 375:1969–1987. DOI: 10.1016/S0140-6736(10)60549-1 [PubMed: 
20466419] 
2. Berry AM, Yother J, Briles DE, Hansman D, Paton JC. Reduced virulence of a defined 
pneumolysin-negative mutant of Streptococcus pneumoniae. Infection and immunity. 1989; 
57:2037–2042. [PubMed: 2731982] 
3. Hirst RA, et al. Streptococcus pneumoniae deficient in pneumolysin or autolysin has reduced 
virulence in meningitis. The Journal of infectious diseases. 2008; 197:744–751. DOI: 
10.1086/527322 [PubMed: 18260758] 
4. Zafar MA, Wang Y, Hamaguchi S, Weiser JN. Host-to-Host Transmission of Streptococcus 
pneumoniae Is Driven by Its Inflammatory Toxin, Pneumolysin. Cell Host Microbe. 2017; 21:73–
83. DOI: 10.1016/j.chom.2016.12.005 [PubMed: 28081446] 
5. Paton JC, Rowan-Kelly B, Ferrante A. Activation of human complement by the pneumococcal toxin 
pneumolysin. Infection and immunity. 1984; 43:1085–1087. [PubMed: 6698602] 
6. Iliev AI, Djannatian JR, Nau R, Mitchell TJ, Wouters FS. Cholesterol-dependent actin remodeling 
via RhoA and Rac1 activation by the Streptococcus pneumoniae toxin pneumolysin. Proceedings of 
the National Academy of Sciences of the United States of America. 2007; 104:2897–2902. DOI: 
10.1073/pnas.0608213104 [PubMed: 17301241] 
7. McNeela EA, et al. Pneumolysin activates the NLRP3 inflammasome and promotes 
proinflammatory cytokines independently of TLR4. PLoS Pathog. 2010; 6:e1001191.doi: 10.1371/
journal.ppat.1001191 [PubMed: 21085613] 
8. Price KE, Camilli A. Pneumolysin localizes to the cell wall of Streptococcus pneumoniae. J 
Bacteriol. 2009; 191:2163–2168. DOI: 10.1128/JB.01489-08 [PubMed: 19168620] 
9. Gordon S. Alternative activation of macrophages. Nature reviews. Immunology. 2003; 3:23–35. 
DOI: 10.1038/nri978
10. Kang PB, et al. The human macrophage mannose receptor directs Mycobacterium tuberculosis 
lipoarabinomannan-mediated phagosome biogenesis. J Exp Med. 2005; 202:987–999. DOI: 
10.1084/jem.20051239 [PubMed: 16203868] 
11. Taylor PR, Gordon S, Martinez-Pomares L. The mannose receptor: linking homeostasis and 
immunity through sugar recognition. Trends in immunology. 2005; 26:104–110. DOI: 10.1016/j.it.
2004.12.001 [PubMed: 15668126] 
12. Zamze S, et al. Recognition of bacterial capsular polysaccharides and lipopolysaccharides by the 
macrophage mannose receptor. The Journal of biological chemistry. 2002; 277:41613–41623. 
DOI: 10.1074/jbc.M207057200 [PubMed: 12196537] 
13. McGreal EP, et al. The carbohydrate-recognition domain of Dectin-2 is a C-type lectin with 
specificity for high mannose. Glycobiology. 2006; 16:422–430. DOI: 10.1093/glycob/cwj077 
[PubMed: 16423983] 
14. Macedo-Ramos H, et al. Evidence of involvement of the mannose receptor in the internalization of 
Streptococcus pneumoniae by Schwann cells. BMC Microbiol. 2014; 14:211.doi: 10.1186/
s12866-014-0211-9 [PubMed: 25085553] 
15. Macedo-Ramos H, et al. Olfactory ensheathing cells as putative host cells for Streptococcus 
pneumoniae: evidence of bacterial invasion via mannose receptor-mediated endocytosis. Neurosci 
Res. 2011; 69:308–313. DOI: 10.1016/j.neures.2010.12.015 [PubMed: 21192991] 
16. Kadioglu A, Weiser JN, Paton JC, Andrew PW. The role of Streptococcus pneumoniae virulence 
factors in host respiratory colonization and disease. Nat Rev Microbiol. 2008; 6:288–301. DOI: 
10.1038/nrmicro1871 [PubMed: 18340341] 
17. Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat 
Rev Immunol. 2007; 7:454–465. DOI: 10.1038/nri2093 [PubMed: 17525754] 
18. Yasukawa H, Sasaki A, Yoshimura A. Negative regulation of cytokine signaling pathways. Annu 
Rev Immunol. 2000; 18:143–164. DOI: 10.1146/annurev.immunol.18.1.143 [PubMed: 10837055] 
Subramanian et al. Page 14
Nat Microbiol. Author manuscript; available in PMC 2019 May 12.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
19. Chieppa M, et al. Cross-linking of the mannose receptor on monocyte-derived dendritic cells 
activates an anti-inflammatory immunosuppressive program. J Immunol. 2003; 171:4552–4560. 
[PubMed: 14568928] 
20. Paton JC, et al. Purification and immunogenicity of genetically obtained pneumolysin toxoids and 
their conjugation to Streptococcus pneumoniae type 19F polysaccharide. Infect Immun. 1991; 
59:2297–2304. [PubMed: 2050399] 
21. Guilliams M, Bruhns P, Saeys Y, Hammad H, Lambrecht BN. The function of Fcgamma receptors 
in dendritic cells and macrophages. Nat Rev Immunol. 2014; 14:94–108. DOI: 10.1038/nri3582 
[PubMed: 24445665] 
22. Littmann M, et al. Streptococcus pneumoniae evades human dendritic cell surveillance by 
pneumolysin expression. EMBO Mol Med. 2009; 1:211–222. DOI: 10.1002/emmm.200900025 
[PubMed: 20049723] 
23. Rajaram MVS, et al. M. tuberculosis-Initiated Human Mannose Receptor Signaling Regulates 
Macrophage Recognition and Vesicle Trafficking by FcRgamma-Chain, Grb2, and SHP-1. Cell 
Rep. 2017; 21:126–140. DOI: 10.1016/j.celrep.2017.09.034 [PubMed: 28978467] 
24. Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the human 
immune system. Nat Rev Immunol. 2010; 10:490–500. DOI: 10.1038/nri2785 [PubMed: 
20559327] 
25. Schuette V, et al. Mannose receptor induces T-cell tolerance via inhibition of CD45 and up-
regulation of CTLA-4. Proc Natl Acad Sci U S A. 2016; 113:10649–10654. DOI: 10.1073/pnas.
1605885113 [PubMed: 27601670] 
26. Neill DR, et al. Density and duration of pneumococcal carriage is maintained by transforming 
growth factor beta1 and T regulatory cells. Am J Respir Crit Care Med. 2014; 189:1250–1259. 
DOI: 10.1164/rccm.201401-0128OC [PubMed: 24749506] 
27. Dorrington MG, et al. MARCO is required for TLR2- and Nod2-mediated responses to 
Streptococcus pneumoniae and clearance of pneumococcal colonization in the murine 
nasopharynx. J Immunol. 2013; 190:250–258. DOI: 10.4049/jimmunol.1202113 [PubMed: 
23197261] 
28. Shak JR, et al. Novel role for the Streptococcus pneumoniae toxin pneumolysin in the assembly of 
biofilms. mBio. 2013; 4doi: 10.1128/mBio.00655-13
29. McKenzie EJ, et al. Mannose receptor expression and function define a new population of murine 
dendritic cells. J Immunol. 2007; 178:4975–4983. [PubMed: 17404279] 
30. Martinez-Pomares L, et al. Carbohydrate-independent recognition of collagens by the macrophage 
mannose receptor. European journal of immunology. 2006; 36:1074–1082. DOI: 10.1002/eji.
200535685 [PubMed: 16619293] 
Subramanian et al. Page 15
Nat Microbiol. Author manuscript; available in PMC 2019 May 12.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Fig. 1. Pneumolysin inhibits cytokine responses and inflammatory signalling in DCs by 
upregulating SOCS1.
(a) TNF-α secretion from human dendritic cells (DCs) (N=6), THP-1 macrophages (N=4), 
and primary neutrophils (N=4) upon infection with wild type strain T4R or its isogenic 
pneumolysin (PLY) mutant T4R∆ply. Data are mean±SEM. *P < 0.05 by Wilcoxon 
matched-pairs signed (two-tailed) rank test. (b) TNF-α secretion from DCs infected with 
encapsulated strains, T4 or T4∆ply (N=3 donors). Data are mean±S.E.M. P < 0.05 by 
Wilcoxon matched-pairs signed (two-tailed) rank test. (c) SOCS1 mRNA levels in T4R or 
T4R∆ply infected DCs at 9 hrs post infection (pi) (N=3 donors). Data are mean±S.E.M. P < 
0.05 by paired two-tailed t test. (d) Flow cytometry histogram plot showing SOCS1 protein 
levels in T4R or in T4R∆ply infected DCs at 9 hrs pi. Percentage of SOCS1+ cells is 
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indicated within the parenthesis. (e) STAT1 phosphorylation in T4R or in T4R∆ply infected 
DCs at 3-5 hrs pi. Data in d,e are representative of 3 independent experiments. (f) Western 
blot showing the levels of nuclear NF-κB (p65) in T4R or T4R∆ply infected DCs at 4 hrs pi. 
Histone H2A served as loading controls. Blots are representative of data from 2 independent 
experiments.
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Fig. 2. MRC-1 co-localizes with pneumolysin and intracellular pneumococci in DCs.
(a) Representative sensorgram of three independent surface plasmon resonance experiments 
showing the dose-dependent binding profile of recombinant PLY (12.5-200 nM) over 
immobilized MRC-1. (b) ELISA showing the binding of immobilized MRC-1 constructs, 
CTLD4-7-Fc or CR-FNII-CTLD1-Fc (1.25-10 μg/ml) with full-length pneumolysin (PLY), 
toxoid PdB, PLY domains 1-3 and domain 4. Mannan (Man) was used as a specific ligand 
for CTLD4-7 to block interaction with PLY, and galactose (Gal) was used as a negative 
control for the blocking assay. Bound PLY was detected using anti-PLY antibodies. Data are 
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mean±S.E.M of two independent experiments, each containing 3 replicates per condition. (c) 
Wild type (WT) DCs or MRC-1 siRNA treated DCs were incubated with purified active 
PLY or mutant PLY (PdB) (200 ng/ml) for 45 min. Immunofluorescence staining show that 
active PLY co-localizes with MRC-1 and EEA-1 (early endosomes) in contrast to the non-
pore forming mutant PLY (PdB). (d) DCs were infected with T4R or T4R∆ply for 90 min. 
Immunofluorescence staining showed that intracellular T4R co-localizes with MRC-1, while 
T4R∆ply does not co-localize with MRC-1, but with lysosomes (lysotracker) (white arrows). 
All scale bars, 5 μm. Data in c,d are representative of three independent experiments.
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Fig. 3. Depletion of MRC-1 abolishes pneumolysin induced cytokine inhibition and enhances T 
cell activation.
(a) Uptake of T4R and T4R∆ply by WT and MRC-1 siRNA treated DCs (N=3 donors). The 
uptake was expressed as a percentage relative to untreated DCs. Data represent mean ± 
S.E.M. **** denotes P<0.0001 by two-way ANOVA with Bonferroni post-test. (b) Wild 
type DCs (control) or MRC-1 siRNA treated DCs were infected with T4R and secretion of 
IL-12, TNF-α and IL-6 was measured in culture supernatants (N=3 donors). Data represent 
mean ± S.E.M. **** denotes P<0.0001 and ** denotes P<0.01 by two-way ANOVA with 
Subramanian et al. Page 20
Nat Microbiol. Author manuscript; available in PMC 2019 May 12.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Bonferroni post-test. (c-d) Wild type or MRC-1 siRNA treated DCs were infected with T4R, 
T4R∆ply or recombinant PLY (rPLY) (200 ng/mL) for 24 hrs and co-cultured with naïve 
CD4+ T cells for 5 days. Secretion of (c) IFN-γ and (d) IL-4 was measured in culture 
supernatants (N=5 donors). Data represent mean ± S.E.M. **** denotes P<0.0001, ** 
denotes P<0.01, * denotes P<0.05 by two-way ANOVA with Bonferroni post-test. (e) FoxP3 
expression in human naïve CD4+ T cells upon co-culture with DCs (control or MRC-1 
siRNA treated) infected with T4R or T4R∆ply. Data are representative of three independent 
experiments. (f) Percentage FoxP3+ CD4+ T cells upon co-culture with murine BMDMs 
(from wild type or MRC-1-/- mice) that were infected with heat-killed strain D39 or mutant 
derivatives lacking capsule (D39∆cps), PLY (D39∆ply) or a double mutant (D39ΔcpsΔply) 
or purified PLY. Data represent mean ± S.E.M. N=3, two way-ANOVA with Bonferroni 
multiple comparison test. * P < 0.05; **P< 0.01.
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Fig. 4. MRC-1 mediates pneumolysin-induced suppression of early inflammatory responses in 
vivo.
(a) Primary alveolar macrophages were isolated from C57/BL6J mice infected with T4 or 
T4∆ply at 6 hrs pi. Immunofluorescence staining showed that PLY proficient pneumococci 
(T4) co-localize with MRC-1 unlike T4∆ply that co-localizes with the lysosome marker 
(lysotracker). Scale bars, 5μm. Images are representative of data from 5 mice/group. (b) 
TNF-α levels (N=12) and (c) bacterial count (CFU/mL) (N=13) in BALF from mice 
infected with either T4 or T4∆ply at 6 hrs pi. Data are mean ± S.E.M of three independent 
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experiments. **P< 0.01 by Mann-Whitney (two-tailed) test. (d) Levels of TNF-α (N=8), 
and (e) bacterial count (CFU/mL) (N=9) in BALF of mice pretreated with anti-MRC-1 (0.1 
mg/mL) or isotype antibody and infected with strain T4 for 6 hrs. Data are mean ± S.E.M of 
three independent experiments. **P< 0.01 by Mann-Whitney (two-tailed) test. (f) Bacterial 
count (CFU) per mg nasopharyngeal homogenates of wild type or MRC-1-/- mice infected 
with strain D39 over a 14 day carriage experiment. N=6 mice per data point per strain, data 
represent mean ±S.E.M. and analyzed by two-way ANOVA with Tukey’s post-test. (g) 
Model suggested for PLY-mediated immunomodulation. PLY-proficient pneumococci induce 
internalization into alveolar macrophages and DCs via interaction with MRC-1. PLY-
expressing pneumococci co-localize with MRC-1 in non-lysosomal compartments and block 
inflammatory cytokine secretion by upregulating SOCS1, thereby promoting regulatory T 
cell responses and bacterial survival in the airways. **P< 0.01, *** P< 0.001.
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